Effect of Intravitreal Injection of Bevacizumab on Acute Central Serous Chorioretinopathy Patients Who Visited Feiz Hospital during 2014-2015 Period.

Autor:	Akhlaghi MR; Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Nasrollahi C; Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Namgar SM; Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Kianersi F; Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Dehghani AR; Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran., Arefpour R; Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Jazyk:	angličtina
Zdroj:	Advanced biomedical research [Adv Biomed Res] 2017 Oct 16; Vol. 6, pp. 125. Date of Electronic Publication: 2017 Oct 16 (Print Publication: 2017).
DOI:	10.4103/abr.abr_193_15
Abstrakt:	Background: Aim of this clinical trial is the evaluation of the effect of intravitreal injection of bevacizumab on acute central serous chorioretinopathy (CSC). Materials and Methods: In a nonrandomized clinical trial, 36 CSC eyes (with <1-month disease history) were examined. Initially, all the patients underwent posterior and anterior segment examinations as well as complete eye examination to evaluate the best spectacle-corrected visual acuity (BSCVA). Then, optical coherence tomography was performed to confirm the diagnosis. The patients were divided to the two groups each of 18 subjects, which 18 patients received intravitreal injection of bevacizumab (1.25 mg) and the rest of them did not receive any treatment (control group). The patients were health checked by the end of the 1 st and 3 rd months. Significance level was considered as P < 0.05. Results: In the BSCVA, no significant difference in visual improvement was observed in baseline vision compared to each other ( P = 0.481). There was also no significant difference in the vision of intervention and control groups 1 and 3 months after injection ( P = 0.379 and P = 0.557). A significant decrement existed in the intervention group compared with the control group in the maximum central macular thickness at 1 month after injection ( P = 0.001); however, the difference was not significant when comparing the two groups at baseline and 3 months after injection ( P = 0.925 and P = 0.338). Conclusion: In general, according to the results of this study, intravitreal injection of bevacizumab was not effective in improvement of patients with acute CSC, although it had no side effects. Competing Interests: There are no conflicts of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu